Journal
CANCERS
Volume 13, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/cancers13122929
Keywords
tumor homing; EPI-X4; CXCR4; biparatopic nanoparticles; tumor targeting; drug delivery
Categories
Funding
- Agencia Estatal de Investigacion (AEI)
- Fondo Europeo de Desarrollo Regional (FEDER) [BIO2016-76063-R, PID2019-105416RB-I00/AEI/10.13039/501100011033]
- AGAUR [2017SGR-229 GRC, 2017SGR-865 GRC, 2018FI_B2_00051]
- CIBER-BBN (project NANOPROTHER)
- CIBER-BBN project 4NanoMets
- CIBER-BBN project NANOREMOTE
- ISCIII [PIE15//00028, PI18/00650]
- EU COST Action [CA 17140]
- ICREA ACADEMIA award
- Ministerio de Ciencia e Innovacion [FPU18/04615]
- Miguel Servet contract from ISCIII - European Social Fund (ESF investing in your future) [CP19/00028]
Ask authors/readers for more resources
This study investigated the use of the human albumin-derived peptide, EPI-X4, as a suitable ligand for targeting colorectal cancer via the cell surface protein CXCR4. Biparatopic nanoparticles combining EPI-X4 with another ligand, T22, showed significantly improved biodistribution in mouse models of CXCR4(+) human cancer and enhanced target cell death. This approach offers a novel strategy for highly selective drug delivery in cancer therapy.
Simple Summary Aimed at minimizing side toxicities cancer therapies require appropriate functional vehicles at the nanoscale, for receptor-mediated tumor-targeted drug delivery. The aim of the present study was to explore the human peptide EPI-X4 as a CXCR4-targeting agent in self-assembled, protein-only nanoparticles. While the systemic tumor biodistribution of EPI-X4-based materials is modest, this peptide shows potent proapoptotic effects on CXCR4(+) cancer cells. Interestingly, the in vivo selectivity of EPI-X4 was dramatically improved, once combined into biparatopic nanoparticles, with a second CXCR4 ligand, the peptide T22. Biparatopic nanoparticles promote a highly selective tumor destruction in a mouse model of human colorectal cancer, probably associated to the CXCR4 antagonist role of EPI-X4. This study not only validates a new human ligand of the tumoral marker CXCR4, but it also offers a novel strategy for the combination, in protein nanoparticles, of dual acting ligands of tumoral markers for highly selective drug delivery. The accumulated molecular knowledge about human cancer enables the identification of multiple cell surface markers as highly specific therapeutic targets. A proper tumor targeting could significantly avoid drug exposure of healthy cells, minimizing side effects, but it is also expected to increase the therapeutic index. Specifically, colorectal cancer has a particularly poor prognosis in late stages, being drug targeting an appropriate strategy to substantially improve the therapeutic efficacy. In this study, we have explored the potential of the human albumin-derived peptide, EPI-X4, as a suitable ligand to target colorectal cancer via the cell surface protein CXCR4, a chemokine receptor overexpressed in cancer stem cells. To explore the potential use of this ligand, self-assembling protein nanoparticles have been generated displaying an engineered EPI-X4 version, which conferred a modest CXCR4 targeting and fast and high level of cell apoptosis in tumor CXCR4(+) cells, in vitro and in vivo. In addition, when EPI-X4-based building blocks are combined with biologically inert polypeptides containing the CXCR4 ligand T22, the resulting biparatopic nanoparticles show a dramatically improved biodistribution in mouse models of CXCR4(+) human cancer, faster cell internalization and enhanced target cell death when compared to the version based on a single ligand. The generation of biparatopic materials opens exciting possibilities in oncotherapies based on high precision drug delivery based on the receptor CXCR4.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available